Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU

Stockholm, 22 July 2020 —Swedish genetic test developer Devyser’s product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic use in the EU. The kit is based on Devyser’s patented next-generation sequencing library prep technology and provides targeted sequencing of 12 genes with a recognized connection to the development …

Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU Read More »